Spesolimab & IL-36R Inhibitors in GPP — PatSnap Eureka
Spesolimab & IL-36R Inhibitors in Generalized Pustular Psoriasis
The IL-36 receptor axis is the central mechanistic driver of GPP flares. Patent intelligence reveals how spesolimab achieves pustule clearance within 48 hours — and how the pipeline is evolving toward subcutaneous maintenance and biomarker-directed therapy.
Why the IL-36 Receptor Is the Central GPP Target
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening inflammatory skin disease characterized by episodic acute flares of sterile pustulation, systemic inflammation, and risk of multi-organ involvement. First described by von Zumbusch in 1909, GPP prevalence is noted as low as 176 per million — underscoring its orphan disease character.
The IL-36 receptor (IL-36R) is activated by three cognate ligands — IL-36α, IL-36β, and IL-36γ. When unblocked, IL-36R signaling drives downstream activation of proinflammatory and pro-fibrotic pathways, resulting in epithelial cell, fibroblast, and immune cell-mediated inflammation that perpetuates the pustular cascade. Blocking IL-36R at a single point interrupts all three activating cytokines simultaneously, making it a highly efficient upstream therapeutic strategy.
A subset of GPP patients carry IL36RN mutations — loss-of-function variants in the IL-36 receptor antagonist gene — which amplify IL-36 pathway activation. Retrieved data explicitly notes that three of seven patients in an early clinical cohort were IL36RN mutation-positive, signaling this genotype as a pharmacogenomic stratifier of interest. The clinical assessment framework most prominently cited includes the GPPGA and GPPASI scoring systems, along with ERASPEN diagnostic criteria.
Secondary molecular targets referenced in the broader dataset include IL-17 (targeted by secukinumab, per Novartis filings in the PatSnap life sciences database), IL-23A/p19, and the IL-12/23 p40 subunit — all representing adjacent cytokine pathways explored before the IL-36 axis was specifically elucidated for GPP.
IL-36R Inhibitors & Adjacent Pipeline Approaches in GPP
Five distinct therapeutic modalities are represented in the retrieved GPP patent dataset, spanning anti-IL-36R, anti-IL-17, anti-IL-17RA, and anti-IL-23A approaches.
Anti-IL-36R Monoclonal Antibodies (Spesolimab)
Spesolimab is a humanized antagonistic monoclonal IgG1 antibody that blocks human IL-36R signaling by competitively preventing activation by all three cognate IL-36 ligands. The IP portfolio spans US, AU, WO, CL, CA, IN, MX, and BR jurisdictions, capturing acute flare IV dosing, subcutaneous maintenance, pediatric extension (≥12 years), and combination-ready frameworks. Filed claims describe multi-indication IP strategies consistent with a global commercial protection approach.
10 mg/kg IV single dose · 900 mg IV × 2 · 300 mg SC q4w maintenanceAnti-IL-36R for Palmoplantar Pustulosis (PPP)
A distinct sub-cluster of Boehringer Ingelheim filings addresses palmoplantar pustulosis — a related pustular condition sharing IL-36 axis pathobiology — using the same anti-IL-36R antibody class. PPP-specific dosing regimens are claimed, with efficacy endpoints including PPP Area and Severity Index (PPPASI) improvement. Retrieved data describes clinical remission thresholds of up to 90% of patients achieving PPPASI 50 at Week 16 as claimed endpoint benchmarks.
PPPASI 50 at Week 16 · PPP PGA endpointsAnti-IL-17 Antagonists in GPP (Secukinumab)
Novartis AG filings address GPP treatment using IL-17 antibodies, specifically secukinumab. The mechanism involves blockade of IL-17A signaling, which operates downstream of the Th17 cell differentiation axis. Retrieved data describes weekly loading doses (150–300 mg) followed by monthly maintenance dosing, with up-titration and down-titration protocols disclosed. These filings predate the IL-36R-specific data in this dataset, suggesting IL-17 targeting represented an earlier line of investigation before the IL-36 axis was more specifically elucidated.
150–300 mg weekly loading · Phase 2/3 signalsIL-17RA Antagonists for Anti-TNF-Experienced Patients
Kirin-Amgen, Inc. filings cover a specific clinical scenario: administration of an IL-17RA antagonist (receptor-level blockade, distinct from IL-17A ligand targeting) to patients with pustular psoriasis or psoriatic erythroderma who have been treated with or cannot receive anti-TNF-alpha antibodies. Active EP and CA filings position this as a sequencing or switch strategy for refractory pustular psoriasis. See how biopharma teams use PatSnap for sequencing intelligence.
Anti-TNF-experienced patients · EP & CA active filingsGPP Pipeline Data: Assignee Distribution & Clinical Response
Patent filing distribution and clinical response data extracted from the GPP IL-36R inhibitor dataset via PatSnap Eureka analysis.
GPP Patent Filings by Assignee & Modality
Boehringer Ingelheim dominates with 15+ anti-IL-36R filings; Novartis and Kirin-Amgen hold smaller IL-17 axis portfolios.
Spesolimab Dosing Strategy Evolution: IV Flare to SC Maintenance
Patent filings trace a clear progression from high-dose IV flare treatment to subcutaneous maintenance regimens — consistent with long-term positioning.
Key Strategic Signals from the GPP IP Dataset
Actionable intelligence for drug developers, IP counsel, and R&D teams navigating the GPP biologics landscape.
48-Hour Flare Response Is the Primary Differentiator
Speed of pustule clearance — within 48 hours to 1 week — is the primary clinical differentiator claimed for IL-36R inhibition in retrieved data, distinguishing this mechanism from the slower-acting IL-17 and IL-23 pathway inhibitors. Drug developers should prioritize rapid flare response as a clinical endpoint in any competitive GPP program.
IL36RN & miR-223 as Nascent Companion Biomarker Opportunities
IL36RN mutation status and miR-223-3p/5p represent nascent companion biomarker opportunities. The retrieved dataset signals these are being actively claimed, and developers of competing or complementary GPP therapies should monitor whether validated assays for these biomarkers become available for patient stratification or treatment monitoring.
Key Patent Holders in the GPP Biologics Space
Mapping the IP landscape across anti-IL-36R, anti-IL-17, and anti-IL-23 modalities for generalized pustular psoriasis.
| Assignee | Primary Target | GPP-Specific Filings | Jurisdictions | Key Indication Focus |
|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | Anti-IL-36R | 15+ distinct filings | US, AU, WO, CL, CA, IN, MX, BR | GPP flare, maintenance, PPP, pediatric ≥12 yrs, biomarkers |
| Boehringer Ingelheim International GmbH | Anti-IL-23A | 2 filings (CA 2017, AU 2025) | CA, AU | GPP (CA filing explicitly), inflammatory skin diseases |
| Novartis AG | Anti-IL-17 (Secukinumab) | 3 filings (EP, US, US) | EP, US | GPP, PPP — earlier therapeutic hypothesis, pre-IL-36R era |
| Kirin-Amgen, Inc. | Anti-IL-17RA | 2 active filings (EP, CA) | EP, CA | Anti-TNF-experienced pustular psoriasis & erythroderma |
Track Emerging GPP Competitors with PatSnap Eureka
Monitor new filings, prosecution updates, and adjacency moves across the full IL-36 axis IP estate — updated continuously via PatSnap Analytics.
Combination Approaches & Next-Generation GPP Strategies
Multiple signals in the retrieved dataset suggest active development of combination strategies and new directions beyond the established spesolimab flare/maintenance paradigm. The evolution from intravenous (900 mg × 2 doses or 10 mg/kg single dose) to subcutaneous regimens (300–600 mg initial, 150–300 mg q4w/q12w maintenance) represents a formulation and delivery direction consistent with long-term maintenance positioning.
Multiple US and AU Boehringer Ingelheim filings (active status, 2021–2025) contain explicit language covering concurrent, prior, and subsequent administration of anti-IL-36R antibodies with other therapeutic agents — with timing windows specified from 1 hour to 3 months offset. This suggests the IP architecture is being structured to accommodate combination regimens, even if specific co-agents are not enumerated in the retrieved claims. For teams exploring life sciences IP strategy, this combination-ready framework is a key signal to monitor.
The 2017 Canadian Boehringer Ingelheim filing specifically names GPP as a target indication for anti-IL-23A antibodies, and the 2025 AU filing covers the broader IL-23 inflammatory disease portfolio — suggesting that IL-23A targeting may complement IL-36R blockade in refractory or recurrent GPP. The WHO recognizes psoriatic diseases as a significant global health burden, reinforcing the clinical urgency of these combination strategies.
Multiple filings explicitly extend spesolimab indications to adolescents ≥12 years of age (WO, US filings from 2024–2025), representing a translational expansion signaling clinical investigation in younger patient populations — an area tracked continuously via PatSnap's open data API.
Spesolimab & IL-36R Inhibitors in GPP — Key Questions Answered
Spesolimab is a humanized antagonistic monoclonal IgG1 antibody that blocks human IL-36R signaling. The mechanism involves competitive blockade of the receptor, preventing activation by all three cognate IL-36 ligands (IL-36α, IL-36β, and IL-36γ) and thereby interrupting the downstream proinflammatory cascade at its proximal point.
Within 48 hours of a single 10 mg/kg IV dose of an anti-IL-36R antibody, pustule clearance was observed in 3 of 7 patients. GPPGA score of 0 or 1 was achieved in 5 of 7 patients at Week 1, and all patients achieved GPPGA 0 or 1 by Week 4.
For acute flare treatment: single or repeat intravenous dosing (e.g., 10 mg/kg IV; two 900 mg IV doses administered less than 2 weeks apart) for rapid pustule clearance during active GPP episodes. For maintenance/prevention: subcutaneous administration (300 mg or 600 mg initial dose, followed by 150 mg or 300 mg every 4 weeks or every 12 weeks) for flare prevention in adults and adolescents ≥12 years with a GPP history.
An Australian patent filing (2026 publication date) explicitly claims use of miR-223-3p and miR-223-5p as biomarkers to monitor anti-IL-36R treatment — a disclosure unique in the dataset that suggests active pharmacodynamic marker development accompanying the clinical program.
A subset of GPP patients carry IL36RN mutations (loss-of-function mutations in the IL-36 receptor antagonist gene), which amplify IL-36 pathway activation. Retrieved data explicitly notes that three of seven patients in an early clinical cohort were IL36RN mutation-positive. IL36RN mutation status is noted as a biomarker of interest for patient stratification.
Boehringer Ingelheim International GmbH dominates the GPP-specific IP landscape with the largest number of retrieved patents directed at anti-IL-36R antibodies for GPP treatment and prevention. Their portfolio spans at least 15 distinct patent filings. Novartis AG appears as a secondary GPP-relevant assignee with IL-17 antagonist patents, and Kirin-Amgen, Inc. holds active IP for IL-17RA antagonism in pustular psoriasis.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About GPP PatentsNavigate the GPP Biologics Landscape with Confidence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and IP strategy in rare disease and dermatology.
References
- Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis — Boehringer Ingelheim International GmbH, 2025, US [Patent]
- Methods for the treatment and prevention of generalized pustular psoriasis (GPP) — Boehringer Ingelheim International GmbH, 2026, AU [Patent]
- Methods for the treatment and prevention of GPP — Boehringer Ingelheim International GmbH, 2025, WO [Patent]
- Methods for the treatment and prevention of GPP — Boehringer Ingelheim International GmbH, 2024, WO [Patent]
- Methods for the treatment and prevention of GPP — Boehringer Ingelheim International GmbH, 2024, US [Patent]
- Use of Anti-IL-36R antibodies for treatment of generalized pustular psoriasis — Boehringer Ingelheim International GmbH, 2019, CA [Patent]
- Use of Anti-IL-36R antibodies for treatment of generalized pustular psoriasis — Boehringer Ingelheim International GmbH, 2019, WO [Patent]
- Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis — Boehringer Ingelheim International GmbH, 2020, AU [Patent]
- Methods for the treatment of GPP — Boehringer Ingelheim International GmbH, 2023, AU [Patent]
- Methods for the treatment of GPP — Boehringer Ingelheim International GmbH, 2022, WO [Patent]
- Biomarkers associated with anti-IL-36R antibody treatment in generalized pustular psoriasis — Boehringer Ingelheim International GmbH, 2022, WO [Patent]
- Biomarkers associated with anti-IL-36R antibody treatment in generalized pustular psoriasis — Boehringer Ingelheim International GmbH, 2022, US [Patent]
- Anti-IL-36R antibodies for treatment of palmoplantar pustulosis — Boehringer Ingelheim International GmbH, 2020, WO [Patent]
- Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists — Novartis AG, 2016, EP [Patent]
- Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists — Sander, Oliver / Novartis, 2016, US [Patent]
- Method for treating psoriasis patient which received anti-TNF-alpha antibody therapy — Kirin-Amgen, Inc., 2017, EP [Patent]
- Use of IL-23 antibodies for treating generalized pustular psoriasis — Boehringer Ingelheim International GmbH, 2017, CA [Patent]
- Methods of treating inflammatory diseases — Boehringer Ingelheim International GmbH, 2025, AU [Patent]
- GPPGA and GPPASI clinical scoring systems for generalized pustular psoriasis — PubMed Central / NIH
- Psoriasis Fact Sheet — World Health Organization (WHO)
- European Medicines Agency — Orphan Disease Designation Framework
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent data reflects a snapshot of retrieved records and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.